60 Degrees Pharmaceuticals, Inc. Common Stock Net Assets
60 Degrees Pharmaceuticals, Inc. Common Stock net assets. Based on the latest financial reports, 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) has net assets worth $2.53 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.28 Million) and total liabilities ($1.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore SXTP year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.53 Million |
| % of Total Assets | 59.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1.51 |
Net Assets of 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
Net assets of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025. This chart illustrates how 60 Degrees Pharmaceuticals, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See 60 Degrees Pharmaceuticals, Inc. Common net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
The table below shows the annual net assets of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025. For live market cap and overall valuation, see 60 Degrees Pharmaceuticals, Inc. Common (SXTP) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.38 Million | -14.55% |
| 2024-12-31 | $3.96 Million | -17.57% |
| 2023-12-31 | $4.80 Million | +119.87% |
| 2022-12-31 | $-24.15 Million | -33.02% |
| 2021-12-31 | $-18.15 Million | -0.46% |
| 2020-12-31 | $-18.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 60 Degrees Pharmaceuticals, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2951143200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
60 Degrees Pharmaceuticals, Inc. Common Stock Net Assets Breakdown (December 2025)
60 Degrees Pharmaceuticals, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $116.00 | 0.00% |
| Other Comprehensive Income | $142.60K | 4.12% |
| Other Components | $51.21 Million | 1478.80% |
| Total Equity | $3.46 Million | 100.00% |
60 Degrees Pharmaceuticals, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of 60 Degrees Pharmaceuticals, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Sources Energy N.V
AS:NSE
|
$3.31 Million |
|
XTL Biopharmaceuticals Ltd
TA:XTLB
|
$3.31 Million |
|
Coloseum Holding a.s.
PR:COLOS
|
$3.31 Million |
|
N2OFF Inc
NASDAQ:NITO
|
$3.31 Million |
|
WestKam Gold Corp
V:WKG
|
$3.31 Million |
|
Azitra Inc
NYSE MKT:AZTR
|
$3.30 Million |
|
AEST.MED.INT.HLD.SP.ADR/3
F:3FMA
|
$3.30 Million |
|
NIOX Group PLC
LSE:NIOX
|
$3.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 60 Degrees Pharmaceuticals, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,035,600 to 3,463,177, a change of -572,423 (-14.2%).
- Net loss of 7,368,325 reduced equity.
- New share issuances of 6,452,887 increased equity.
- Other comprehensive income increased equity by 7,127.
- Other factors increased equity by 335,888.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.37 Million | -212.76% |
| Share Issuances | $6.45 Million | +186.33% |
| Other Comprehensive Income | $7.13K | +0.21% |
| Other Changes | $335.89K | +9.7% |
| Total Change | $- | -14.18% |
Book Value vs Market Value Analysis
This analysis compares 60 Degrees Pharmaceuticals, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.20x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-722.96 | $1.01 | x |
| 2021-12-31 | $-726.13 | $1.01 | x |
| 2022-12-31 | $-973.92 | $1.01 | x |
| 2023-12-31 | $201.18 | $1.01 | x |
| 2024-12-31 | $35.50 | $1.01 | x |
| 2025-12-31 | $5.17 | $1.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 60 Degrees Pharmaceuticals, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -212.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -732.82%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.55x
- Recent ROE (-212.76%) is below the historical average (-81.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -139.08% | 0.84x | 0.00x | $-1.28 Million |
| 2021 | 0.00% | -366.42% | 0.83x | 0.00x | $-2.49 Million |
| 2022 | 0.00% | -2769.49% | 0.17x | 0.00x | $-3.82 Million |
| 2023 | -77.32% | -1485.06% | 0.03x | 1.60x | $-4.25 Million |
| 2024 | -196.93% | -1308.01% | 0.11x | 1.43x | $-8.35 Million |
| 2025 | -212.76% | -732.82% | 0.19x | 1.55x | $-7.71 Million |
Industry Comparison
This section compares 60 Degrees Pharmaceuticals, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) | $2.53 Million | 0.00% | 0.69x | $3.31 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About 60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications… Read more